CORDIS · 282095 · FP7
TARKINAID Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases
Coordinator: SEMMELWEIS EGYETEM (HU)
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant consortium have recently obtained genetic evidence showing that myeloid Src-family kinases (Hck, Fgr and Lyn) are indispensable for murine models of autoimmune inflammatory diseases such as rheumatoid a…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €3.0M toward a total project budget of €3.9M — a funding rate of 77%, with the remainder covered by the consortium partners. The project runs over approximately 4 years from 2012-01-01 to 2015-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from HU
see all →- HCEMM — Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership with EMBL739593 · H2020 · €15.0M
- EPIC — Centre of Excellence in Production Informatics and Control739592 · H2020 · €10.9M
- DYNASNET — Dynamics and Structure of Networks810115 · H2020 · €9.3M
- DALIA — Danube Region Water Lighthouse Action101094070 · HORIZON · €8.5M
- DETERMINISTIC6G — DETERMINISTIC E2E COMMUNICATION WITH 6G101096504 · HORIZON · €5.5M
- MOMENTUM PPDF — Momentum Premium Postdoctoral fellowship101179854 · HORIZON · €5.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-FP funding scheme.
- What is the EU contribution?
- The European Commission contributes €3.0M toward a total project budget of €3.9M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by SEMMELWEIS EGYETEM (HU).
- What is the project timeline?
- The project runs from 2012-01-01 to 2015-12-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 282095.